TG Therapeutics Future Growth
Future criteria checks 6/6
TG Therapeutics is forecast to grow earnings and revenue by 56.5% and 34.7% per annum respectively. EPS is expected to grow by 56.2% per annum. Return on equity is forecast to be 48.1% in 3 years.
Key information
56.5%
Earnings growth rate
56.2%
EPS growth rate
| Biotechs earnings growth | 42.7% |
| Revenue growth rate | 34.7% |
| Future return on equity | 48.1% |
| Analyst coverage | Good |
| Last updated | 08 Nov 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 746 | 286 | 260 | 205 | 6 |
| 12/31/2025 | 541 | 164 | 135 | 144 | 9 |
| 12/31/2024 | 329 | 24 | -29 | -19 | 9 |
| 9/30/2024 | 265 | -14 | -28 | -28 | N/A |
| 6/30/2024 | 347 | 96 | 68 | 68 | N/A |
| 3/31/2024 | 289 | 41 | 20 | 20 | N/A |
| 12/31/2023 | 234 | 13 | -31 | -31 | N/A |
| 9/30/2023 | 190 | -26 | -42 | -42 | N/A |
| 6/30/2023 | 24 | -176 | -160 | -160 | N/A |
| 3/31/2023 | 9 | -169 | -167 | -167 | N/A |
| 12/31/2022 | 3 | -198 | -176 | -176 | N/A |
| 9/30/2022 | 5 | -239 | -239 | -239 | N/A |
| 6/30/2022 | 7 | -288 | -272 | -272 | N/A |
| 3/31/2022 | 8 | -326 | -283 | -283 | N/A |
| 12/31/2021 | 7 | -348 | -296 | -296 | N/A |
| 9/30/2021 | 4 | -343 | -261 | -261 | N/A |
| 6/30/2021 | 2 | -345 | -251 | -250 | N/A |
| 3/31/2021 | 1 | -319 | -234 | -234 | N/A |
| 12/31/2020 | 0 | -279 | -215 | -215 | N/A |
| 9/30/2020 | 0 | -231 | -193 | -193 | N/A |
| 6/30/2020 | 0 | -206 | -170 | -170 | N/A |
| 3/31/2020 | 0 | -189 | -162 | -162 | N/A |
| 12/31/2019 | 0 | -173 | -133 | -133 | N/A |
| 9/30/2019 | 0 | -187 | -136 | -136 | N/A |
| 6/30/2019 | 0 | -159 | -136 | -136 | N/A |
| 3/31/2019 | 0 | -167 | -134 | -134 | N/A |
| 12/31/2018 | 0 | -173 | -129 | -129 | N/A |
| 9/30/2018 | 0 | -150 | -117 | -117 | N/A |
| 6/30/2018 | 0 | -148 | N/A | -107 | N/A |
| 3/31/2018 | 0 | -132 | N/A | -100 | N/A |
| 12/31/2017 | 0 | -118 | N/A | -94 | N/A |
| 9/30/2017 | 0 | -111 | N/A | -89 | N/A |
| 6/30/2017 | 0 | -105 | N/A | -81 | N/A |
| 3/31/2017 | 0 | -92 | N/A | -67 | N/A |
| 12/31/2016 | 0 | -78 | N/A | -62 | N/A |
| 9/30/2016 | 0 | -72 | N/A | -57 | N/A |
| 6/30/2016 | 0 | -61 | N/A | -53 | N/A |
| 3/31/2016 | 0 | -62 | N/A | -52 | N/A |
| 12/31/2015 | 0 | -63 | N/A | -45 | N/A |
| 9/30/2015 | 0 | -64 | N/A | -47 | N/A |
| 6/30/2015 | 0 | -68 | N/A | -44 | N/A |
| 3/31/2015 | 0 | -63 | N/A | -36 | N/A |
| 12/31/2014 | 0 | -56 | N/A | -35 | N/A |
| 9/30/2014 | 0 | -43 | N/A | -25 | N/A |
| 6/30/2014 | 0 | -30 | N/A | -18 | N/A |
| 3/31/2014 | 0 | -24 | N/A | -17 | N/A |
| 12/31/2013 | 0 | -20 | N/A | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NKB2 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1%).
Earnings vs Market: NKB2 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: NKB2 is expected to become profitable in the next 3 years.
Revenue vs Market: NKB2's revenue (34.7% per year) is forecast to grow faster than the German market (5.6% per year).
High Growth Revenue: NKB2's revenue (34.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: NKB2's Return on Equity is forecast to be very high in 3 years time (48.1%).